IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA room temperature stability and storage products, today announced the appointment of David V. Smith as Chief Operating Officer.

David V. Smith has more than 30 years of financial and operational management experience, and has held leadership positions in the biotechnology industry for more than two decades. Most recently, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, a company he joined in 1999. At Chiron, he held a number of increasingly responsible positions including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Prior to Chiron, Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997, Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation.

“Of all the advances in life science technology, the integration of complex chemistry and biology systems is now made possible by the practical utilization of microfluidics technology. The resulting sample-to-answer solutions are revolutionizing medical care, medical discovery and other applications that affect our health and safety,” said Mr. Smith. “I am particularly excited to join IntegenX just as the company prepares to launch the first microfluidics-based rapid DNA human identification system for the law enforcement, defense, forensics and security markets.”

Mr. Smith is currently chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc. and was previously chair of the Audit Committee and a Director of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University.

Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX commented: “David has been part of the executive leadership and management of the biotechnology industry since its inception in the 1980s, including working within large public companies operating in highly regulated markets. Having played a key role in pioneering companies such as Genentech, Chiron, and Thoratec, we are proud to have him join us at this exciting phase of growth at IntegenX as we lead the establishment of the emerging rapid DNA identification industry.”

Learn about the Apollo 324 System for automated next-generation sequencing library preparation at the annual meeting of ASHG, the American Society of Human Genetics. November 6-10, 2012, San Francisco, California

IntegenX to integrate IP into system for rapid human DNA identification and take over supplying consumable products to GE’s MegaBACE™ customers

IntegenX Inc., a privately held company that is a leader in the emerging field of rapid human DNA identification, today announced that it has acquired SV Corp, a wholly owned subsidiary of GE Healthcare Bio-Sciences. IntegenX will leverage SV Corp’s products and intellectual property assets to expand its consumables offering and to accelerate the commercialization of its RapidHIT™ 200 Human DNA Identification System. GE Healthcare Bio-Sciences is a subsidiary of GE Healthcare. Financial terms of the agreement were not disclosed.

“This acquisition marks an important milestone in IntegenX’s introduction of our first commercially available system for rapid human DNA identification,” said Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX. “The SV Corp acquisition brings to IntegenX proprietary products and a proven and protected IP estate containing key technical know-how in capillary electrophoresis, separation, sample preparation, and separation matrix.”

As a result of the acquisition, IntegenX will take over supplying capillaries and matrix to the more than 100 existing users of GE’s MegaBACE™ sequencers. These products will also be integrated into the RapidHIT™ system.

Set to commercially launch later this year, the IntegenX RapidHIT 200 is a self-contained Human Identification (HID) system that automates and accelerates the process of producing standardized DNA profiles from mouth swabs and other human samples in less than 90 minutes. Numerous local, state, national, and international law enforcement and security agencies use DNA-based human identification to make informed identification decisions regarding the arrest, detention, or release of suspects, as well as to analyze crime scene evidence. The RapidHIT system will allow rapid DNA analysis at the point of collection — such as on arrest or detention — a new approach in the usage of DNA profiles as an actionable biometric similar to fingerprints.

Learn about Rapid DNA and the RapidHIT 200 System, the first fully automated swab-to-profile system for DNA-based human identification, at ISHI — the International Symposium on Human Identification. October 15-18, 2012 in Nashville, Tennessee.

Learn about Rapid DNA and the RapidHIT 200 Human Identification System. Visit integenX at IACP 2012, the 119th Annual International Association of Chiefs of Police Conference and Law Enforcement Education and Technology Exposition in San Diego, California. September 29 – October 3, 2012.

Visit integenX at ICG Americas 2012, the inaugural International Conference on Genomics, in Philadelphia, Pennsylvania. Septembber 28-30, 2012. Learn how the Apollo 324 System automates next-generation sequencing library preparation workflows for all popular NGS platforms.

IntegenX Inc., a privately held company that is leading the emerging field of rapid human DNA identification, today announced that Louis E. Grever, former Executive Assistant Director, Science and Technology Branch of the Federal Bureau of Investigation (FBI), has joined the company’s Board of Directors.

“Rapid DNA analysis is a transformative technology that will fundamentally change the way investigations are conducted by enabling law enforcement personnel to quickly and definitively identify suspects while they are in custody,” said Mr. Grever. “I believe this technology will create safer communities through its many applications from policing to homeland security and defense. I look forward to working with IntegenX as they introduce the first rapid DNA systems to the market this year.”

Mr. Grever recently retired from a 24-year career with the FBI. He began as a Special Agent in 1988, and was promoted to a series of positions of increasing responsibility throughout his tenure. Upon the formation of the new FBI Science and Technology Branch (STB) in 2006, Mr. Grever was assigned to the Office of the Director and served as the first Special Assistant to the STB Executive Assistant Director. In 2007, he was promoted to Deputy Assistant Director and placed in charge of the Special Technologies and Applications Office, a new entity within the STB authorized to develop and deploy innovative technical and analytical tools and capabilities for the FBI. Later in 2007, Mr. Grever was selected as the deputy to the STB Executive Assistant Director. In October 2008, he was appointed by the Director to serve as the STB Executive Assistant Director. In this role, Mr. Grever was responsible for all of the FBI’s forensic, biometric, and applied technology support to law enforcement delivered by the FBI Laboratory, Criminal Justice Information Services, and Operational Technology Divisions.

“Louis was instrumental in introducing the FBI’s Rapid DNA Initiative and in setting a vision for DNA as a fast identification tool to aid law enforcement,” said Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX. “His involvement and counsel will be invaluable as we prepare to launch our RapidHIT™ 200 Human Identification System in the U.S. and globally.”

The IntegenX RapidHIT 200 is a mobile, self-contained Human Identification (HID) system that automates and accelerates the process of producing standardized DNA profiles from mouth swabs and other human samples in less than 90 minutes. Numerous local, state, national, and international law enforcement and security agencies use DNA-based human identification to make informed identification decisions regarding the arrest, detention, or release of suspects, as well as to analyze crime scene evidence. The RapidHIT 200 system will allow, for the first time, rapid DNA analysis at the point of collection — such as on arrest or detention — setting a new standard in the usage of DNA profiles as an actionable biometric similar to fingerprints.

Learn about our RapidHIT™ 200 Human Identification System, the first fully automated swab to profile system for STR-based HID. Visit us at the 2012 Biometric Consortium Conference and Technology Expo in Tampa, Florida. September 18-20, 2012.

Learn about the RapidHIT 200 Human Identification System, the first fully automated swab-to-profile system for DNA-based human identification, at the 6th European Academy of Forensic Science Conference, August 20-24, in The Hague, The Netherlands.

Visit integenX at the FBINAA 2012 Annual Training Conference, July 28 – August 1, in Grapevine, Texas. Learn about our RapidHIT™ 200 Human Identification System, the first fully automated swab-to-profile system for STR-based human identification. Booth 714.